ASND Ascendis Total Debt to Capital

Ascendis Pharma A/S (ASND) revenue is based on the sale of innovative TransCon hGH drugs for the treatment of endocrine pathologies. This debt-to-equity chart demonstrates the current metric 0.30, which is critical given the high cash burn associated with clinical trials. However, steady demand for Skytrofa creates a high-margin cash flow, offsetting financial risks and ensuring business resilience.

Asset managers require an objective assessment of an issuer's financial stability for risk control. This ratio measures the proportion of debt capital relative to equity, determining the business's degree of dependence on creditors. The dynamics of the debt-to-equity ratio reflect the impact of market asset revaluations on leverage. Excessive debt is critical for Ascendis Pharma A/S (ASND), whose revenues depend on international patent protection. Geopolitical barriers could restrict market access, thereby increasing the debt burden.